Related Experiment Video
Updated: Nov 2, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
41.0K
INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
David M G Halpin1, Sally Worsley2, Afisi S Ismaila3,4
1University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
ERJ Open Research
|June 10, 2021
Summary
Single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) improved COPD patient outcomes more than multiple-inhaler triple therapy (MITT). This real-world study found FF/UMEC/VI led to greater health status and lung function improvements.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Real-world data comparing single-inhaler triple therapy (MITT) with multiple-inhaler triple therapy (MITT) in COPD patients are limited.
- The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus MITT was assessed in a usual clinical care setting.
Purpose of the Study:
- To compare the effectiveness of once-daily FF/UMEC/VI with clinician-chosen MITT in COPD patients.
- To evaluate health status improvement, lung function changes, and inhalation technique errors.
Main Methods:
- A multicentre, randomised, open-label, phase IV effectiveness study (INTREPID) was conducted in five European countries.
- 3092 COPD patients were randomized to receive either FF/UMEC/VI via the ELLIPTA inhaler or a non-ELLIPTA MITT.
- The primary endpoint was the proportion of COPD Assessment Test (CAT) responders at week 24.
Main Results:
- Significantly more patients were CAT responders with FF/UMEC/VI compared to non-ELLIPTA MITT (OR 1.31, p<0.001).
- Mean change from baseline in FEV1 was significantly greater with FF/UMEC/VI (50 mL difference, p<0.001).
- Critical inhalation technique errors were low in both groups (6% for FF/UMEC/VI, 3% for MITT).
Conclusions:
- Once-daily single-inhaler FF/UMEC/VI demonstrated superior effectiveness compared to non-ELLIPTA MITT in a real-world COPD setting.
- FF/UMEC/VI led to significantly greater improvements in patient health status and lung function.
- The safety profiles were similar between the two treatment groups.
Related Concept Videos
01:23Inhaled Medications
504
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
504
01:26COPD: Management Using Bronchodilators and Corticosteroids
504
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
504
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.1K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.1K
01:30Asthma-IV: Diagnostic and Management
2.8K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.8K
01:22Chronic Obstructive Pulmonary Disease
1.8K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.8K